mutLBSgeneDB |
Gene summary for NFYA |
Gene summary |
Basic gene Info. | Gene symbol | NFYA |
Gene name | nuclear transcription factor Y, alpha | |
Synonyms | CBF-A|CBF-B|HAP2|NF-YA | |
Cytomap | UCSC genome browser: 6p21.3 | |
Type of gene | protein-coding | |
RefGenes | NM_002505.4, NM_021705.3, | |
Description | CAAT box DNA-binding protein subunit ACAAT-box DNA binding protein subunit ACCAAT-binding transcription factor subunit BHAP2 CCAAT-binding proteinTranscription factor NF-Y, A subunitnuclear transcription factor Y subunit Anuclear transcription facto | |
Modification date | 20141207 | |
dbXrefs | MIM : 189903 | |
HGNC : HGNC | ||
HPRD : 01793 | ||
Protein | UniProt: P23511 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_NFYA | |
BioGPS: 4800 | ||
Pathway | NCI Pathway Interaction Database: NFYA | |
KEGG: NFYA | ||
REACTOME: NFYA | ||
Pathway Commons: NFYA | ||
Context | iHOP: NFYA | |
ligand binding site mutation search in PubMed: NFYA | ||
UCL Cancer Institute: NFYA | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0006355 | regulation of transcription, DNA-templated | 15243141 |
Top |
Ligand binding site mutations for NFYA |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | R317 | R317Q | UCEC | 2 | R310 | R310W | UCEC | 1 | R312 | R312C | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for NFYA |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | R317 | R317Q | -1.0730915 | R310 | R310W | -0.86297646 | R312 | R312C | -0.44230661 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for NFYA from PDB |
PDB ID | PDB title | PDB structure | 4AWL | The NF-Y transcription factor is structurally and functionally a sequence specific histone |
Top |
Differential gene expression and gene-gene network for NFYA |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for NFYA |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0024121 | Lung Neoplasms | 1 | Biomarker |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for NFYA |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of NFYA go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
Top |
Conservation information for LBS of NFYA |
Multiple alignments for P23511 in multiple species |
LBS | AA sequence | # species | Species | A307 | SRHRHAMARKR | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | F318 | GEGGRFFSPKE | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | F319 | EGGRFFSPKEK | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | G315 | RKRGEGGRFFS | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | G316 | KRGEGGRFFSP | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H300 | RRKYLHESRHR | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H304 | LHESRHRHAMA | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H306 | ESRHRHAMARK | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | L299 | ERRKYLHESRH | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | M308 | RHRHAMARKRG | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | R303 | YLHESRHRHAM | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | R310 | RHAMARKRGEG | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | R312 | AMARKRGEGGR | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | R317 | RGEGGRFFSPK | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | S302 | KYLHESRHRHA | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | S320 | GGRFFSPKEKD | 3 | Homo sapiens, Rattus norvegicus, Bos taurus |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |